Ankur Drugs & Pharma Ltd. - Research Center
531683 ANKURDRUGS Group (T) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 12 | Mar ' 12 | Sep ' 11 | Mar ' 11 | Sep ' 10 | |
|---|---|---|---|---|---|
| Sales | 68.78 | 76.44 | 76.65 | 271.42 | 552.57 |
| Operating profit | -3.71 | -18.88 | -17.75 | 14.40 | 118.21 |
| Interest | 50.17 | 50.95 | 17.01 | 57.41 | 55.34 |
| Gross profit | -53.86 | -69.81 | -34.72 | -42.60 | 63.27 |
| EPS (Rs) | -44.96 | -80.74 | -33.81 | -52.15 | 18.07 |
Half yearly
results in details
| Sep ' 12 | Mar ' 12 | Sep ' 11 | Mar ' 11 | Sep ' 10 | |
|---|---|---|---|---|---|
| Other income | 0.03 | 0.02 | 0.04 | 0.41 | 0.40 |
| Stock adjustment | -0.55 | 5.39 | 13.29 | 46.80 | -7.18 |
| Raw material | 47.91 | 55.35 | 38.58 | 168.66 | 403.09 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 10.90 | 13.68 | 15.23 | 16.97 | 12.76 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 14.22 | 20.89 | 22.40 | 24.59 | 25.70 |
| Provisions made | - | - | 4.90 | - | - |
| Depreciation | 33.10 | 31.73 | 30.68 | 41.12 | 19.69 |
| Taxation | - | 31.27 | - | 20.11 | 8.63 |
| Net profit / loss | -86.96 | -156.17 | -65.40 | -100.87 | 34.95 |
| Extra ordinary item | - | -23.37 | - | 2.95 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 19.34 | 19.34 | 19.34 | 19.34 | 19.34 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | 170.40 | 161.21 | 158.19 | 146.02 | 144.36 |
| Agg.of non promotoholding (%) | 88.10 | 83.35 | 81.79 | 75.49 | 74.64 |
| OPM (%) | -5.40 | -24.69 | -23.16 | 5.31 | 21.39 |
| GPM (%) | -78.27 | -91.30 | -45.28 | -15.67 | 11.44 |
| NPM (%) | -126.38 | -204.26 | -85.28 | -37.11 | 6.32 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis